US EditionPublished • loading... • Updated
Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program
Inhibrx has enrolled 46 of 60 patients in INBRX-106 Phase 2/3 trial and completed enrollment for ozekibart expansion cohorts, with key data expected by mid-2026.
Summary by The Billings Gazette
11 Articles
11 Articles
The Billings Gazette+10 Reposted by 10 other sources
Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program
SAN DIEGO, Dec. 16, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology today announced an update on the INBRX-106 Phase 2/3 clinical trial in combination with…
·Billings, United States
Read Full ArticleCoverage Details
Total News Sources11
Leaning Left0Leaning Right0Center6Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
